89Bio Inc., a clinical-stage biopharmaceutical company, has announced the approval of non-qualified stock options for three new employees. These options, allowing the purchase of a total of 64,750 shares of the company's common stock, were granted on September 1, 2025. The stock options will vest over four years, with 25% vesting after the first year of employment and the remaining shares vesting in equal quarterly installments. This initiative is part of 89Bio's effort to strengthen its workforce as the company continues to develop innovative therapies for liver and cardiometabolic diseases.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 89Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524152-en) on September 05, 2025, and is solely responsible for the information contained therein.